The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer - Wikidata - wikimedia - TriplyDB

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

http://www.wikidata.org/entity/Q33862290

about

Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancers HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling.Protein mislocalization: mechanisms, functions and clinical applications in cancer.The oncogenic potential of human cytomegalovirus and breast cancer.Small interfering RNA (siRNA)-mediated knockdown of macrophage migration inhibitory factor (MIF) suppressed cyclin D1 expression and hepatocellular carcinoma cell proliferation Therapeutic Considerations in Treating HER2-Positive Metastatic Breast Cancer Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts.YSY01A, a Novel Proteasome Inhibitor, Induces Cell Cycle Arrest on G2 Phase in MCF-7 Cells via ERα and PI3K/Akt Pathways.TIPE2 Inhibits Lung Cancer Growth Attributing to Promotion of Apoptosis by Regulating Some Apoptotic Molecules Expression.Treatment of HER2-positive breast cancer.Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer P-mTOR Expression and Implication in Breast Carcinoma: A Systematic Review and Meta-Analysis Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression.Immunohistochemical prediction of lapatinib efficacy in advanced HER2-positive breast cancer patients.Past, present, and future challenges in breast cancer treatment.3-Phosphoinositide-dependent protein kinase-1 as an emerging target in the management of breast cancer.The unpluggable in pursuit of the undruggable: tackling the dark matter of the cancer therapeutics universe.Integrated in vivo genetic and pharmacologic screening identifies co-inhibition of EGRF and ROCK as a potential treatment regimen for triple-negative breast cancer.Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.Cordycepin induces autophagy-mediated c-FLIPL degradation and leads to apoptosis in human non-small cell lung cancer cells.Phosphorylated ribosomal S6 (p-rpS6) as a post-treatment indicator of HER2 signalling targeted drug resistance.Biological underpinnings of breastfeeding challenges: the role of genetics, diet, and environment on lactation physiology.Targeting the mTOR pathway in breast cancer.NF-κB as the main node of resistance to receptor tyrosine kinase inhibitors in triple-negative breast cancer.Afatinib down-regulates MCL-1 expression through the PERK-eIF2α-ATF4 axis and leads to apoptosis in head and neck squamous cell carcinoma Pictilisib PI3Kinase inhibitor (a phosphatidylinositol 3-kinase [PI3K] inhibitor) plus paclitaxel for the treatment of hormone receptor-positive, HER2-negative, locally recurrent, or metastatic breast cancer: interim analysis of the multicentre, pla High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.Metformin and Cancer Treatment.Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance.Combined drug therapeutic strategies for the effective treatment of Triple Negative Breast Cancer.The PI3K/Akt/mTOR pathway regulates the replicative senescence of human VSMCs.Severe Burn-Induced Intestinal Epithelial Barrier Dysfunction Is Associated With Endoplasmic Reticulum Stress and Autophagy in Mice.CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion Cancer stem cells and HER2 positive breast cancer: The story so far The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers Upregulation of macrophage migration inhibitory factor promotes tumor metastasis and correlates with poor prognosis of pancreatic ductal adenocarcinoma

P2860

Q28071388-7AFB43F5-664A-4939-8D92-347B6F10DA0F Q28081872-17A92090-D13C-44A8-9061-0D6ACD830487 Q28551145-FB409FA1-59E2-407A-A38C-5EBCB6D92BCE Q33726847-B2E4C165-AF4F-4795-A2BB-1CB58A05D9EC Q34076405-BDD5E4DA-3990-4074-89F7-1280F0C9911A Q34081724-C21D1449-E51E-4219-915F-143C488DE044 Q34221613-556C58E6-958A-459D-9201-69FE936055E2 Q34268618-33DECA84-B4B7-453E-883F-EA8FCA8354E1 Q34441761-98E599A2-1D8B-465E-9472-1AE72801CF00 Q35148080-07E514DF-94F3-46C4-A76E-E335D711F7A8 Q35577788-2885AAE7-1EC2-470B-B951-4BDDF35CCC3B Q35740877-F05A4282-DC6B-4E65-97EF-6D9FB84178D3 Q36167088-D2A5F123-F951-4C60-9C7F-99CD2353ED95 Q36257635-79F037FB-A1AC-4FCC-95B2-92B3E5F80458 Q36355880-C83433D6-64AB-4C6C-9751-69949FA0AA34 Q36729467-2D2E3CC2-8D5E-4454-AE15-A8563A1B9BEB Q36934273-BA3762AD-99A0-49C8-A428-5FA6F6E28583 Q37167731-F9F5BE21-C95B-4AAF-9CA9-E0C348183C4A Q37385372-8CE7929D-795E-4827-925B-F0293CE68CD8 Q37536415-610D7F96-CA02-422E-935A-85192BF99A14 Q37645090-C089181A-24AC-4358-92CF-EF0B92730100 Q37701664-5388DFB1-B19E-46F6-9C58-FBB585A194EB Q38838851-A90B28A5-C52B-4C71-AABC-7AA89FE8DFA9 Q38847429-FAA353E4-4509-41AB-8D23-AC30B0853B17 Q39390640-89AF5471-391D-46A7-89A8-1F773B2D6B3B Q39400435-D191804E-45D1-47D2-9956-BF3EEE68129D Q40970957-7D4EF436-8B5C-4101-80DE-3A2678E424C9 Q46626206-FF1744C4-EF8F-448D-92D0-B1D72CF8009E Q46952217-E2B87FEE-6A1A-4021-976B-D96C1A60F874 Q47136015-822B10A0-E9AC-45D8-9C39-6AE2F07E4E53 Q47551153-24760300-78E1-4F16-BFF8-ED6DBF6D25A4 Q48551091-D7E1DCD9-48CA-48EF-BE87-C093A3B1BC16 Q51516524-FE2D4C2B-115F-423B-937F-2402DB123CA8 Q55517489-94743DFC-C2B8-4202-95F3-76577ABA76C7 Q57107726-2E7B4223-F622-43F7-BC69-7A9A2B44EACA Q57120564-200922C6-6E05-4272-99EC-2B2A280CD600 Q58702607-68480876-6ED2-462D-87AF-F03B5584098A Q58746018-E3379C06-BCA6-4388-881F-5F34C7BA9D63

P2860

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

http://www.wikidata.org/entity/Q33862290

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@ast

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@en

type

label

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@ast

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@en

prefLabel

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@ast

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@en

P1433

Q33862290-B5C5F3E9-D44B-45E5-9D77-2E76F423BA21

P1476

Q33862290-E76469A2-9CF3-4ED6-84BD-F154B26760E0

P2093

Q33862290-80229F92-C362-40CB-9FF7-20C8751FAE9D

Q33862290-83A27819-980C-40BA-A390-486D08EF06DD

Q33862290-EC0A58C9-B8C7-4668-A6B1-2C17B449ABF1

P2860

Q33862290-007BB078-E4CF-4A8F-A57A-D847804C122B

Q33862290-0174DBBD-E71A-44FE-ADF2-5659BEEC201A

Q33862290-017E2733-F762-4C9B-95A1-03F2290BEF18

Q33862290-09D4EEFD-695B-4170-B99A-1040ABF902E7

Q33862290-0A452C08-59FB-4489-B682-70EF548A14EE

Q33862290-0ABA9AF0-3BAA-477B-BD0E-47914D1D49F2

Q33862290-0FA68070-E4F9-4BE1-9750-4174ACC07D6A

Q33862290-18658326-19E3-4F5C-B6C6-362616A4774E

Q33862290-19AF758D-F93E-46C3-8CA0-F5BE112A5548

Q33862290-1ABE6CBE-07CF-4AE7-B05B-D288ACA19A67

P304

Q33862290-93A45FB5-3340-4A2D-A10B-CEE7F422F911

P31

Q33862290-CDFD9CB7-1CB0-411C-9179-4D4891BB4C77

P356

Q33862290-6510C3F2-5797-4A52-BE55-36C6545A73E7

P433

Q33862290-9BFE47FF-4981-4F58-B5CB-5C7178C6D55B

P478

Q33862290-E74E414C-C22F-4943-A65E-284A29CAA8A1

P577

Q33862290-7294B10A-65B3-4FE2-8B21-DB9573744832

P698

Q33862290-13FE9702-61D0-4709-820C-0C16296E30DA

P932

Q33862290-807AB078-A131-45C5-B403-8BDAB658B5E9

P356

JNCCN.2013.0086

P1433

Journal of the National Comprehensive Cancer Network

P1476

The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer

@en

P2093

Antonio C Wolff

http://www.w3.org/2001/XMLSchema#string

Ben Ho Park

http://www.w3.org/2001/XMLSchema#string

Josh Lauring

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

Comprehensive molecular portraits of human breast tumours

Genome sequencing identifies a basis for everolimus sensitivity

The PI3K pathway as drug target in human cancer

mTOR signaling in growth control and disease

Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer

Knockin of mutant PIK3CA activates multiple oncogenic pathways

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

P304

670-678

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2013.0086

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23744866

http://www.w3.org/2001/XMLSchema#string

P932

4086482

http://www.w3.org/2001/XMLSchema#string